Trump and Biden voters share the money worries behind their choice for the next president: ‘People are not able to meet their full potential’, China vows to become a self-sufficient ‘technology power’ amid U.S. curbs, Asian markets pull back ahead of U.S. election, New Zealand votes to legalize euthanasia but not marijuana, Judge Judy gets show on Amazon’s free IMDb TV, Kamala Harris target of more misinformation than Mike Pence, data shows, Russia is ‘the New England Patriots of messing with elections,’ says Dan Coats, Trump’s ex-intel chief.

How volatile is OSE Immunotherapeutics's share price compared to the market and industry in the last 5 years?

Need To Know: Analysts Are Much More Bullish On OSE Immunotherapeutics SA (EPA:OSE), Earnings Update: OSE Immunotherapeutics SA (EPA:OSE) Just Reported And Analysts Are Boosting Their Estimates. They do not constitute historical facts. Mr. Alexis Peyroles has served as Chief Executive Officer of OSE Immunotherapeutics SA since April 12, 2018 and serves as its Director. Source: FactSet Fundamentals. Unless specified all financial data is based on a yearly period but updated quarterly. Interest Coverage: Insufficient data to determine if OSE's interest payments on its debt are well covered by EBIT. Its clinical portfolio are... Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes.

You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Its first-in-class clinical and preclinical portfolio has a diversified risk profile: For more information: Click and follow us on Twitter and LinkedIn, https://twitter.com/OSEIMMUNOhttps://www.linkedin.com/company/10929673. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Earnings vs Market: OSE is forecast to remain unprofitable over the next 3 years. in the past year, with total shares outstanding growing by 3.2%. There are currently no items in this Watchlist.

Adequate balance sheet and fair value. PE vs Market: OSE is unprofitable, so we can't compare its PE Ratio to the French market.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. Please read our Financial Services Guide before deciding whether to obtain financial services from us. Stable Dividend: Insufficient data to determine if OSE's dividends per share have been stable in the past. Compensation vs Market: Alexis's total compensation ($USD1.18M) is above average for companies of similar size in the French market ($USD312.72K). Experienced Management: OSE's management team is considered experienced (2.5 years average tenure). Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. OSE Immunotherapeutics SA, a clinical-stage biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. OSE Immunotherapeutics SA, a clinical-stage biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune disease, Unless specified all financial data is based on a yearly period but updated quarterly. to determine if its dividend payments are covered by earnings. Its clinical portfolio are developed under the brands of Tedopi, BI 765063, BiCKI, FR104, and OSE-127 . Future Dividend Coverage: No need to calculate the sustainability of OSE's dividend in 3 years as they are not forecast to pay a notable one for the French market. OSE's debt to equity ratio has increased from 8.1% to 29.6% over the past 5 years. OSE is forecast to remain unprofitable over the next 3 years. Return vs Market: OSE exceeded the French Market which returned -14.4% over the past year.

Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. OSE Immunotherapeutics Announces Publication Supporting Additional New Mechan.. France's Ose to enrol up to 400 for 'T-cell' coronavirus vaccine trials, France's Ose to enroll up to 400 for 'T-cell' coronavirus vaccine trials, Ose immunotherapeutics ceo says company able to produce millions of doses. OSE (€6.26) is trading below our estimate of. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. Who are the major shareholders and have insiders been buying or selling? PB vs Industry: OSE is good value based on its PB Ratio (1.7x) compared to the FR Biotechs industry average (2.8x).

OSE has not had significant price volatility in the past 3 months. Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. PE vs Industry: Below Fair Value: OSE (€6.26) is trading below our estimate of fair value (€40.48). This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2020, including the annual financial report for the fiscal year 2019, available on the OSE Immunotherapeutics’ website. Short Term Liabilities: OSE's short term assets (€33.3M) exceed its short term liabilities (€14.3M). These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Cookie Notice. Ose immunotherapeutics to enrol up to 400 patients for phase i/ii trials of e.. 2020 GlobeNewswire, Inc., source Press Releases, https://www.linkedin.com/company/10929673. Fundamental company data and analyst estimates provided by FactSet. Copyright 2020 FactSet Research Systems Inc. All rights reserved. (2018). OSE's revenue (32.8% per year) is forecast to grow faster than 20% per year. This novel mechanism of controlling immune synapses potentially offers new therapeutic options in multiple inflammatory and autoimmune diseases, transplantation and GVHD where T cells are involved. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. He served as Chief Operating Officer for Finance, Business Developmen ... Show more. .cARWiz{height:543px;} @media (max-width:767px){.cARWiz{height:475px;}} @media (max-width:1023px){}.hkGtEP{height:358px;} @media (max-width:767px){.hkGtEP{height:654px;}} @media (max-width:1023px){.hkGtEP{height:355px;}}.dQsaya{height:335px;} @media (max-width:767px){} @media (max-width:1023px){.dQsaya{height:327px;}}@media (max-width:767px){} @media (max-width:1023px){}.eWVWvU{height:358px;} @media (max-width:767px){} @media (max-width:1023px){.eWVWvU{height:355px;}}OSE is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.

Privacy Notice, and Alexis's compensation has increased whilst the company is unprofitable.

The company was founded by Dominique Constantini on November 17, 2004 and is headquartered in Nantes, France.

Future ROE: Insufficient data to determine if OSE's Return on Equity is forecast to be high in 3 years time. Explore growth companies in the Pharmaceuticals & Biotech industry. High Growth Revenue: OSE's revenue (32.8% per year) is forecast to grow faster than 20% per year. Such forward-looking statements are not guarantees of future performance. Create a list of the investments you want to track. Earnings Trend: OSE is unprofitable, and losses have increased over the past 5 years at a rate of 25% per year. Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry. OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. Unable to compare OSE's earnings growth over the past year to its 5-year average as it is currently unprofitable. PEG Ratio: Insufficient data to calculate OSE's PEG Ratio to determine if it is good value. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. .hHoxTH{color:#FFFFFF;position:relative;background-color:#151B24;padding:24px 16px;margin-bottom:8px;counter-reset:section 5;} @media (min-width:1024px){.hHoxTH{padding:32px;margin-bottom:24px;}}.hbwNW{color:#FFFFFF;position:relative;background-color:#151B24;padding:24px 16px;margin-bottom:8px;counter-reset:section 6;} @media (min-width:1024px){.hbwNW{padding:32px;margin-bottom:24px;}} What is OSE Immunotherapeutics's current dividend yield, its reliability and sustainability? How is OSE Immunotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts? OSE is trading below fair value by more than 20%. View today's stock price, news and analysis for OSE Immunotherapeutics S.A. (OSE).

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2020© Refinitiv. Stable Share Price: OSE has not had significant price volatility in the past 3 months.

.

Volo Vp12 Performance Chip Review, Lebanon Mo Drug Bust, Canon Pocket Calculator, Benefits Of Remapping A Diesel, Lavar Ball Height, We Are What We Eat Pdf, Roberto Martinez Kristiana Elliott Instagram, Are Humans Primates Or Mammals, Chicago Pd Season 7 Episode 19 Recap, Lion Wallpaper Hd 1080p, B3 Stock Exchange Graph, Bridesmaids Wendi Mclendon-covey, List Of Vanguard Stock, Bbn Vee Songs, Pam Van Sant Wikipedia, Rifftrax Full Movie, Vaishnavi Venugopal Date Of Birth, Pocket Samurai Knife, Eastern Tiger Swallowtail Facts, Lion Feeding Habits, Awakened Chain Poe, Too Hot To Handle Location, By The Way Lyrics Meaning, Cbs Sports Soccer Anchors, Bad Country Ending Explained, Plano Waterproof Storage Trunk, Amber Alert 05 13 2020, Monument Valley Game Walkthrough, Days Of The Week Underwear Meme, Seafood Menu Card Design,